2023
Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventions
2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screening
2019
Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study
Tan J, Altice FL, Madden LM, Zelenev A. Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study. The Lancet HIV 2019, 7: e121-e128. PMID: 31879250, PMCID: PMC7289179, DOI: 10.1016/s2352-3018(19)30373-x.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNew HIV infectionsHigh HIV burdenHIV infectionMinistry of HealthOAT coverageAgonist therapyHIV burdenHIV incidenceBuprenorphine maintenance therapyPublic Health CenterMaintenance therapyHIV outcomesHIV prevalenceHIV transmissionMedication procurementHIV epidemicHealth centersHIV preventionTreatment goalsPWIDOAT expansionDisease controlSexual riskInfection
2017
Why People Who Inject Drugs Voluntarily Transition Off Methadone in Ukraine
Rozanova J, Marcus R, Taxman FS, Bojko MJ, Madden L, Farnum SO, Mazhnaya A, Dvoriak S, Altice FL. Why People Who Inject Drugs Voluntarily Transition Off Methadone in Ukraine. Qualitative Health Research 2017, 27: 2057-2070. PMID: 28942704, DOI: 10.1177/1049732317732307.Peer-Reviewed Original ResearchPatient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatmentWillingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Bojko MJ, Madden L, Filippovich S, Dvoriak S, Altice FL. Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. International Journal Of Drug Policy 2017, 45: 56-63. PMID: 28628853, PMCID: PMC5533603, DOI: 10.1016/j.drugpo.2017.05.037.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentOpioid-dependent peopleAgonist treatmentCurrent opioid agonist treatmentCross-sectional nationwide surveyMonthly incomeMultivariate logistic regressionIndependent predictorsPWIDKruskal-Wallis testPsychosocial counselingPrevious unsuccessful attemptsYounger ageLogistic regressionDependent peopleHigher incomeOne-way ANOVANationwide surveyDrugsContinuous variablesFamily supportTreatmentLarge percentageBetter access